Phase 1/2a Evaluation of SPK002 Safety, Pharmacokinetics, and Neutralizing Activity for COVID-19 Prophylaxis in Healthy and Immunocompromised Subjects

The primary objective of this study is to evaluate the **safety**, pharmacokinetics, and neutralizing activity of SPK002 as a pre-exposure prophylaxis for COVID-19. This evaluation is conducted in two phases: Phase 1 involves healthy volunteers, while Phase 2a focuses on immunocompromised individuals. The clinical relevance of this study lies in its potential to provide a preventive measure against COVID-19, particularly for those with compromised immune systems who are at higher risk of severe outcomes from the virus.

The clinical trial involves a study population comprising both **immunocompromised individuals** and healthy volunteers, categorized under Phase 2a and Phase 1, respectively. The age range of participants is specified as adults, with both male and female subjects included in the trial. The trial population selection criteria include a focus on vulnerable populations, although specific lifestyle considerations such as diet, physical activity, or habits are not detailed. The total number of participants is not provided, as the sponsor has not disclosed this information. The study does not specify any particular inclusion or exclusion criteria beyond the general health status categories mentioned.

The clinical trial is designed to evaluate the **safety**, pharmacokinetics, and neutralizing activity of SPK002 as a pre-exposure prophylaxis for **COVID-19**. This study is structured in two phases: Phase 1 involves healthy volunteers, while Phase 2a targets immunocompromised individuals. The trial employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from May 23, 2023, to July 1, 2024, encompassing both recruitment and follow-up periods.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized and receive the investigational product or placebo. Subsequent follow-up visits will be scheduled to monitor safety, collect pharmacokinetic data, and evaluate the neutralizing activity of SPK002. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the trial endpoints.

The expected length of participant involvement varies depending on the phase of the trial, with each phase having specific follow-up schedules. Conditions that may lead to early termination from the study include adverse events, withdrawal of consent, or any other situation deemed necessary by the investigator to ensure participant safety. The trial is conducted in accordance with ethical standards and regulatory requirements, ensuring the protection and well-being of all participants throughout the study duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

No specific details regarding the assessment of efficacy in the clinical trial are provided in the available data. The information does not include parameters or endpoints used to evaluate efficacy, nor does it specify the methods, schedule, or tools for measuring, collecting, and analyzing efficacy parameters. The trial is categorized under phase 7, but further details on efficacy assessment are not available.